Review



fak inhibitor pf573228  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Tocris fak inhibitor pf573228
    Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor <t>(PF573228),</t> Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).
    Fak Inhibitor Pf573228, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 193 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf573228/product/Tocris
    Average 95 stars, based on 193 article reviews
    fak inhibitor pf573228 - by Bioz Stars, 2026-03
    95/100 stars

    Images

    1) Product Images from "Kisspeptin Regulates Cell Invasion and Migration in Endometrial Cancer"

    Article Title: Kisspeptin Regulates Cell Invasion and Migration in Endometrial Cancer

    Journal: Journal of the Endocrine Society

    doi: 10.1210/jendso/bvae001

    Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).
    Figure Legend Snippet: Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).

    Techniques Used: Migration, Expressing, Control, Western Blot



    Similar Products

    fak inhibitor pf573228  (MedChemExpress)
    95
    MedChemExpress fak inhibitor pf573228
    Fak Inhibitor Pf573228, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf573228/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    fak inhibitor pf573228 - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    fak inhibitor pf573228  (Tocris)
    95
    Tocris fak inhibitor pf573228
    Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor <t>(PF573228),</t> Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).
    Fak Inhibitor Pf573228, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf573228/product/Tocris
    Average 95 stars, based on 1 article reviews
    fak inhibitor pf573228 - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    fak inhibitor pf573228  (Selleck Chemicals)
    95
    Selleck Chemicals fak inhibitor pf573228
    Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor <t>(PF573228),</t> Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).
    Fak Inhibitor Pf573228, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf573228/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    fak inhibitor pf573228 - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    recombinant proteins fak inhibitor pf573228 selleck chemicals  (Selleck Chemicals)
    95
    Selleck Chemicals recombinant proteins fak inhibitor pf573228 selleck chemicals
    Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor <t>(PF573228),</t> Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).
    Recombinant Proteins Fak Inhibitor Pf573228 Selleck Chemicals, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant proteins fak inhibitor pf573228 selleck chemicals/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    recombinant proteins fak inhibitor pf573228 selleck chemicals - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    fak inhibitor pf573228  (Cayman Chemical)
    90
    Cayman Chemical fak inhibitor pf573228
    Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor <t>(PF573228),</t> Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).
    Fak Inhibitor Pf573228, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf573228/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    fak inhibitor pf573228 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    trypsin thermo fisher scientific 25200056 egm singlequot kit lonza 204579 fak inhibitor pf573228  (Thermo Fisher)
    99
    Thermo Fisher trypsin thermo fisher scientific 25200056 egm singlequot kit lonza 204579 fak inhibitor pf573228
    Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor <t>(PF573228),</t> Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).
    Trypsin Thermo Fisher Scientific 25200056 Egm Singlequot Kit Lonza 204579 Fak Inhibitor Pf573228, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trypsin thermo fisher scientific 25200056 egm singlequot kit lonza 204579 fak inhibitor pf573228/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    trypsin thermo fisher scientific 25200056 egm singlequot kit lonza 204579 fak inhibitor pf573228 - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).

    Journal: Journal of the Endocrine Society

    Article Title: Kisspeptin Regulates Cell Invasion and Migration in Endometrial Cancer

    doi: 10.1210/jendso/bvae001

    Figure Lengend Snippet: Kisspeptin agonist-KP10 and antagonist-KP234 significantly regulated the migration and invasion of endometrial cancer cells through FAK, Src, and ERK1/2-mediated MMP-2/9 expression. (A) The treatment with KP10 significantly decreased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. Meantime, the challenge with KP234 significantly increased MMP-2/9 protein expression in RL95-2 endometrial cancer cell line when compared with the normal control. (B) To verify the effects of FAK, Src, and ERK1/2 inhibitors in RL95-2 endometrial cancer cells, cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated expressions of FAK, Src, and ERK1/2 were inhibited by FAK, Src, and ERK1/2 inhibitors individually. (C) RL95-2 endometrial cancer cells were pretreated with FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually, and then treated with KP234 for 2 hours. Cell lysates were collected for immunoblot analysis. The KP234-stimulated MMP-2/9 expression was weakened by FAK inhibitor (PF573228), Src inhibitor (SU6656), and ERK1/2 inhibitor (U0126) individually. Results are expressed as mean ± SEM of 3 independent experiments (* P < .05 vs control).

    Article Snippet: The FAK inhibitor PF573228 (Tocris Bioscience Cat#3239, RRID:AB_3076559), the Src inhibitor SU6656 (Tocris Bioscience Cat#6475, RRID: AB_3076557), and the ERK1/2 inhibitor U0126 (Sigma-Aldrich, Cat#U120, RRID: AB_3076557) were purchased from Tocris Bioscience (Bristol, UK) and Sigma-Aldrich Chemie GmbH (Steinheim, Germany).

    Techniques: Migration, Expressing, Control, Western Blot